Literature DB >> 19430304

Temporal changes in causes of death among HIV-infected patients in the HAART era in Rio de Janeiro, Brazil.

Antonio G Pacheco1, Suely H Tuboi, Silvia B May, Luiz F S Moreira, Luciana Ramadas, Estevão P Nunes, Mônica Merçon, José C Faulhaber, Lee H Harrison, Mauro Schechter.   

Abstract

BACKGROUND: The widespread use of highly active antiretroviral therapy (HAART) has led to marked decreases in death rates in Brazil in HIV-infected individuals. Nonetheless, there are scarce data on specific causes of death.
METHODS: Death rates from a cohort of HIV-infected patients in Rio de Janeiro, Brazil, were analyzed in 2-year periods, from 1997 to 2006. Poisson models and survival models accounting for competing risks were used to assess association of covariables. A standardized validated algorithm was used to ascertain specific causes of death.
RESULTS: Of the 1538 eligible patients, 226 (14.7%) died during the study period, corresponding to a mortality rate of 3.2 per 100 person-years. The median follow-up time was 4.61 years (interquartile range = 5.63 years) and the loss to follow-up rate was 2.4 per 100 person-years. Overall, 98 (43.4%) were classified as non-AIDS-related causes. Although opportunistic infections were the leading causes of death (37.6%), deaths due to AIDS-related causes declined significantly over time (P < 0.01). In the most recent period (2005-2006), the rate of non-AIDS-related causes of deaths was higher than that of AIDS-related causes of death.
CONCLUSIONS: In the HAART era, there has been a significant change in causes of death among HIV-infected patients in Rio de Janeiro. As access to HAART improves, integration with other public programs will become critically important for the long-term success of HIV/AIDS programs in developing countries.

Entities:  

Mesh:

Year:  2009        PMID: 19430304      PMCID: PMC2748737          DOI: 10.1097/QAI.0b013e3181a4ecf5

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  24 in total

1.  Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts.

Authors:  François Dabis; Eric Balestre; Paula Braitstein; Paolo Miotti; W G Martin Brinkhof; Martin Schneider; Mauro Schechter; Christian Laurent; Andrew Boulle; Charles Kabugo; Gorana Capkun; Catherine Seyler; James McIntyre; Eduardo Sprinz; David Bangsberg; Stefan Van der Borght; Matthias Egger
Journal:  Int J Epidemiol       Date:  2005-09-12       Impact factor: 7.196

2.  Tutorial in biostatistics: competing risks and multi-state models.

Authors:  H Putter; M Fiocco; R B Geskus
Journal:  Stat Med       Date:  2007-05-20       Impact factor: 2.373

3.  Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Authors:  Frank J Palella; Rose K Baker; Anne C Moorman; Joan S Chmiel; Kathleen C Wood; John T Brooks; Scott D Holmberg
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

4.  Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism.

Authors:  Robert J Glynn; Bernard Rosner
Journal:  Am J Epidemiol       Date:  2005-10-05       Impact factor: 4.897

5.  Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City.

Authors:  Judith E Sackoff; David B Hanna; Melissa R Pfeiffer; Lucia V Torian
Journal:  Ann Intern Med       Date:  2006-09-19       Impact factor: 25.391

6.  Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3.

Authors:  Bryan Lau; Stephen J Gange; Richard D Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2007-02-01       Impact factor: 3.731

7.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

8.  CD4+ count-guided interruption of antiretroviral treatment.

Authors:  W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

9.  Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion.

Authors:  Colette Smit; Ronald Geskus; Sarah Walker; Caroline Sabin; Roel Coutinho; Kholoud Porter; Maria Prins
Journal:  AIDS       Date:  2006-03-21       Impact factor: 4.177

10.  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.

Authors:  Paula Braitstein; Martin W G Brinkhof; François Dabis; Mauro Schechter; Andrew Boulle; Paolo Miotti; Robin Wood; Christian Laurent; Eduardo Sprinz; Catherine Seyler; David R Bangsberg; Eric Balestre; Jonathan A C Sterne; Margaret May; Matthias Egger
Journal:  Lancet       Date:  2006-03-11       Impact factor: 79.321

View more
  30 in total

1.  Estimating the extent of underreporting of mortality among HIV-infected individuals in Rio de Janeiro, Brazil.

Authors:  Antonio G Pacheco; Valeria Saraceni; Suely H Tuboi; Lilian M Lauria; Lawrence H Moulton; José Cláudio Faulhaber; Bonnie King; Jonathan E Golub; Betina Durovni; Solange Cavalcante; Lee H Harrison; Richard E Chaisson; Mauro Schechter
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-07       Impact factor: 2.205

2.  Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial.

Authors:  Alan R Lifson; Jacqueline Neuhaus; Jose Ramon Arribas; Mary van den Berg-Wolf; Ann M Labriola; Timothy R H Read
Journal:  Am J Public Health       Date:  2010-08-19       Impact factor: 9.308

3.  Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men.

Authors:  Keri N Althoff; Lisa P Jacobson; Ross D Cranston; Roger Detels; John P Phair; Xiuhong Li; Joseph B Margolick
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-10-14       Impact factor: 6.053

4.  Abstracts of the HIV & Hepatitis in the Americas 2017 - Congress.

Authors: 
Journal:  J Int AIDS Soc       Date:  2017-04-06       Impact factor: 5.396

5.  Outcomes for critically ill patients with HIV and severe sepsis in the era of highly active antiretroviral therapy.

Authors:  Jared A Greenberg; Jeffrey L Lennox; Greg S Martin
Journal:  J Crit Care       Date:  2011-10-26       Impact factor: 3.425

6.  Sepsis is a major determinant of outcome in critically ill HIV/AIDS patients.

Authors:  André M Japiassú; Rodrigo T Amâncio; Emerson C Mesquita; Denise M Medeiros; Helena B Bernal; Estevão P Nunes; Paula M Luz; Beatriz Grinsztejn; Fernando A Bozza
Journal:  Crit Care       Date:  2010-08-10       Impact factor: 9.097

7.  Sex and Racial/Ethnic Differences in Premature Mortality Due to HIV: Florida, 2000-2009.

Authors:  Mary Jo Trepka; Theophile Niyonsenga; Kristopher P Fennie; Karma McKelvey; Spencer Lieb; Lorene M Maddox
Journal:  Public Health Rep       Date:  2015 Sep-Oct       Impact factor: 2.792

8.  Mortality and causes of death among HIV-infected individuals in the country of Georgia: 1989-2012.

Authors:  Nikoloz Chkhartishvili; Lali Sharvadze; Otar Chokoshvili; Natalia Bolokadze; Nino Rukhadze; Russell R Kempker; Amiran Gamkrelidze; Jack A DeHovitz; Carlos Del Rio; Tengiz Tsertsvadze
Journal:  AIDS Res Hum Retroviruses       Date:  2014-02-24       Impact factor: 2.205

9.  U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008.

Authors:  Keri N Althoff; Kate Buchacz; H Irene Hall; Jinbing Zhang; David B Hanna; Peter Rebeiro; Stephen J Gange; Richard D Moore; Mari M Kitahata; Kelly A Gebo; Jeffrey Martin; Amy C Justice; Michael A Horberg; Robert S Hogg; Timothy R Sterling; Angela Cescon; Marina B Klein; Jennifer E Thorne; Heidi M Crane; Michael J Mugavero; Sonia Napravnik; Gregory D Kirk; Lisa P Jacobson; John T Brooks
Journal:  Ann Intern Med       Date:  2012-09-04       Impact factor: 25.391

10.  Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era.

Authors:  Beatriz Grinsztejn; Paula M Luz; Antonio G Pacheco; Desiree V G Santos; Luciane Velasque; Ronaldo I Moreira; Maria Regina C Guimarães; Estevão P Nunes; Alberto S Lemos; Sayonara R Ribeiro; Dayse P Campos; Marco A A Vitoria; Valdilea G Veloso
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.